Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

95468934

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the patient community to guide the drug development process. “Patients should be providing input and guidance throughout the entire drug review process,” said Marc Boutin, Executive VP and COO of the National Health Council. Boutin highlighted the improvements made through PDUFA V to open up and enhance the Agency’s interaction and engagement with patients. “Integrating our perspective into how drugs are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Investor Forum Kicks Off Amid Industry Optimism

San Francisco skyline

Today, the BIO Investor Forum kicks off in San Francisco, Calif. BioWorld’s Catherine Shaffer paints a positive picture of the industry (subscription required) highlighting the strong IPO activity and heightened interest in the sector among investors. The conference reflects the upward momentum of the industry with increased expected attendance among both companies and investors. The JOBS Act is widely viewed as the underlying reason for these positive trends in the industry as the law helped Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

JOBS Act Deconstructed: Regulatory Relief

Capitol

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. The JOBS Act marks a key departure from the previous one-size-fits-all regulatory approach for companies conducting a public offering.  Emerging growth companies (EGCs) are now subject Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

JOBS Act Deconstructed: Regulation D

150639480

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act.  BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage.  Since the JOBS Act passed, attention has focused mostly on the law’s effects on the IPO market.  This is largely because the IPO On-Ramp was the Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

JOBS Act: Rule 506 Goes Into Effect Today

DC in Fall

Since Congress passed the Jumpstart our Business Startups (JOBS) Act last spring, there have been 39 IPOs in the biotech industry – and counting!  Today, another provision from the JOBS Act takes effect that will further enhance biotech capital formation. Pursuant to rules mandated by the JOBS Act, companies are now able to use general solicitation to advertise to investors when conducting an offering under Rule 506 of SEC Regulation D.  Rule 506 is a Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,